Clinical Trial Update: Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of intensity-modulated radiation therapy with nivolumab for recurrent or second primary head and neck squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Emory University | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19